Article: Percutaneous Carillon Mitral Contour System Deployment Followed by CRT-D Implantation: First Case Report from Oman

Mitral valve regurgitation (MR) is a common problem in patients with cardiac issues especially those with dilated cardiomyopathy (DCM) due to mitral annular dilatation and malcoaptation of the mitral valve leaflets. Although DCM is associated with high mortality rates, there has been no global agreement about the best method of treatment. Treatment of MR in such cases can be done by surgery, which has many limitations due to high-risk concerns. MR may also be managed by other alternatives such as mitral-clip and transcoronary venous mitral annuloplasty using the Carillon® Mitral Contour System®. Combined therapy with a cardiac resynchronization therapy defibrillator (CRT-D) and mitral contour can be used in such cases with valuable improvement in general condition in many patients. In our case, we used the Carillon Mitral Contour System for treatment of severe MR in a 64-year-old patient with severely impaired systolic function after implantation of a CRT-D.

Citing Articles

Coronary sinus for cardiac resynchronization therapy: leave it alone and go for the branch! a case report.

DellEra G, Veroli A, Degiovanni A, Patti G Eur Heart J Case Rep. 2022; 6(11):ytac436.

PMID: 36405535 PMC: 9671029. DOI: 10.1093/ehjcr/ytac436.

Alternative methods to overcome the challenging anatomy of the coronary sinus during percutaneous mitral annuloplasty procedure.

Gormel S, Yasar S, Murat E, Koksal O, Yuksel U, Barcin C Anatol J Cardiol. 2021; 25(12):924-925.

PMID: 34866589 PMC: 8654014. DOI: 10.5152/AnatolJCardiol.2021.136.

Outcomes after Transcatheter Mitral Valve Edge to Edge Repair; a Comparison of Two Pathologies.

El-Shurafa H, Albabtain M, Arafat A, Abdulsalam W, Alfonso J, Ashmeik K Acta Cardiol Sin. 2021; 37(3):286-295.

PMID: 33976512 PMC: 8107709. DOI: 10.6515/ACS.202105_37(3).20201020A.

Cardiac resynchronization therapy following Carillon annuloplasty device for symptomatic heart failure and functional mitral regurgitation: a case report.

Jamil H, Goldberg S, Witte K Eur Heart J Case Rep. 2020; 3(4):1-5.

PMID: 31911977 PMC: 6939793. DOI: 10.1093/ehjcr/ytz224.

The Year in Cardiothoracic and Vascular Anesthesia: Selected Highlights from 2019.

Evans A, Weiner M, Shaefi S, Patel P, Townsley M, Kumaresan A J Cardiothorac Vasc Anesth. 2019; 34(1):1-11.

PMID: 31759862 PMC: 7398274. DOI: 10.1053/j.jvca.2019.10.057.

References

1.

Al-Amri H, Al-Moghairi A, El Oakley R . Surgical treatment of functional mitral regurgitation in dilated cardiomyopathy. J Saudi Heart Assoc. 2013; 23(3):125-34. PMC: 3801141. DOI: 10.1016/j.jsha.2011.04.001. View

2.

Koelling T, Aaronson K, Cody R, Bach D, Armstrong W . Prognostic significance of mitral regurgitation and tricuspid regurgitation in patients with left ventricular systolic dysfunction. Am Heart J. 2002; 144(3):524-9. DOI: 10.1067/mhj.2002.123575. View

3.

Trichon B, Felker G, Shaw L, Cabell C, OConnor C . Relation of frequency and severity of mitral regurgitation to survival among patients with left ventricular systolic dysfunction and heart failure. Am J Cardiol. 2003; 91(5):538-43. DOI: 10.1016/s0002-9149(02)03301-5. View

4.

Rose E, Gelijns A, Moskowitz A, Heitjan D, Stevenson L, Dembitsky W . Long-term use of a left ventricular assist device for end-stage heart failure. N Engl J Med. 2002; 345(20):1435-43. DOI: 10.1056/NEJMoa012175. View

5.

Block P . Percutaneous mitral valve repair: are they changing the guard?. Circulation. 2005; 111(17):2154-6. DOI: 10.1161/01.CIR.0000165266.57397.B2. View